如果这一假设得到验证,这些药物将有望用于临床试验中,成为预防CRS治疗方案的一部分。这为未来研究和治疗提供了潜在的新途径,为改善CAR-T细胞疗法的安全性和效果提供了新的方案。 参考资料: 1.Longitudinal plasma proteomics in CAR-T cell therapy patients implicates neutrophils and NETosis in the genesis of CRS...
7. Bailey, S. R. et al. Blockade or deletion of IFNγ reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies. Blood Cancer Discov. 3, 136–153 (2022). 8. Park, J. H. et...
此外CAR T 细胞治疗期间使用糖皮质激素不影响结局的发现,使高危患者对治疗或预防性使用糖皮质激素的实践有更强的信心。综上所述,本研究发现将有助于理解 CRS 的临床后果,并塑造未来 CRS 管理的策略。 参考文献 Shakthi T Bhaskar,et al.Ch...
CAR T cell therapyhematologyimmunologyruxolitinibCytokine release syndrome (CRS) and immune effector cell゛ssociated neurotoxicity are two major CAR T related toxicities. With the interventions of Tocilizumab and steroids, many patients can recover from severe CRS. However, some patients are refractory ...
参考文献: 1.Chen X, Li P, Tian B and Kang X (2022) Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors. Front. Immunol. 13:1079181. doi: 10.3389/fimmu.2022.1079181 2.Wang L, Hong R. New-Onset Severe Cytopenia After CAR-T Cell Therapy: ...
“在难治性CLL患者中,CD19-CAR-T细胞疗法和伊布替尼可带来高反应率,并且无严重的CRS。这种治疗方案对大多数患者来说都是可行的。”Gauthier评论道。 参考资料: https://www.onclive.com/conference-coverage/icml-2019/concurrent-ibrutinib-with-car-tcell-therapy-improves-orr-reduces-severe-crs-in-highrisk-cl...
During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed CAR T-cell therapy as third-line therapy for a patient with relapsed/refractory multiple myeloma and relevance of the KarMMa-3 trial for their treatment.
[21] CHEADLE E J,GORNALL H,BALDAN V,et al.CAR T cells: driving the road from the laboratory to the clinic[J].Immunol Rev,2014,257(1):91-106. [22] BOUHASSIRA D C,THOMPSON J J,DAVILA M L.Using gene therapy to manipulate the immune system in the fight against B-cell leukemias[...
[25] Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma[J]. N Engl J Med, 2020, 382:1331-1342. doi: 10.1056/NEJMoa1914347 [26] HAY K A, HANAFI L...
细胞因子风暴是CAR-T细胞治疗中发生频繁且症状突出的急性毒性反应之一。 图1:CRS的诱导因子 注:Ang-2:Angiopoetin 2,促血管生成素2;DC:树突细胞;MHC-I:主要组织相容性复合体I;NK cell:自然杀伤细胞;PD-(L)1:程序性细胞死亡蛋白(配体)1;TCR:T细胞受体;vWF:血管性血友病因子。